We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Clovis' (CLVS) Rubraca Gets FDA Nod as Maintainence Therapy
Read MoreHide Full Article
Clovis Oncology, Inc. recently announced that the FDA has granted approval to label expansion of its PARP inhibitor, Rubraca (rucaparib). The drug is now approved as a maintenance treatment in recurrent ovarian cancer patients who have received one prior platinum-based chemotherapy. The drug can now also be prescribed irrespective of BRCA-mutation in the second-line setting.
The FDA approval was based on data from the confirmatory phase III study — ARIEL 3 which showed that Rubraca led to significant improvement in progression-free survival in such patients.
Please note that Rubraca had received accelerated approval for the treatment of advanced BRCA-mutant ovarian cancer in third or later line setting in December 2016. With the latest approval, the accelerated approval was converted to regular one for this indication. The drug is under review in Europe for this indication with a decision expected in this quarter.
Shares of Clovis were up 5.9% on Mar 6, after the news surfaced. However, the stock has lost 18.4% so far this year, underperforming the industry’s decline of 11.8%.
With the latest approval, Rubraca comes at par with other approved PARP inhibitors for treatment of ovarian cancer — AstraZeneca’s (AZN - Free Report) Lynparza and TESARO’s Zejula. All the drugs are now approved in patients irrespective of the BRCA-mutation status, creating a level playing field for all the players.
Pfizer (PFE - Free Report) is also evaluating its PARP inhibitor, talazoparib, in a phase I study in several advanced or recurrent solid tumors.
Moreover, earlier this February, the National Comprehensive Cancer Network (“NCCN”) added Rubraca as maintenance therapy for third or later line ovarian cancer patients to its clinical practice guidelines in oncology ovarian cancer.
The year 2018 has started well for Clovis with a positive recommendation for Rubraca’s approval in Europe in third or later line ovarian cancer patients, addition to the NCCN guidelines and the latest label expansion in the United States. Moreover, after a potential approval in Europe, Clovis will seek further approval of the drug as maintenance therapy in the expanded patient population.
These positive developments are expected to boost the company’s top line. However, it remains to be seen how the three PARP inhibitors perform in an equally competing field.
Meanwhile, a phase III confirmatory study, ARIEL4, is evaluating Rubraca compared with chemotherapy on patients, who have failed two prior lines of therapy. Clovis is also looking to expand Rubraca’s label into additional indications, like prostrate, breast and pancreatic cancers, among others either as monotherapy or in combination with other agents.
Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.
Image: Bigstock
Clovis' (CLVS) Rubraca Gets FDA Nod as Maintainence Therapy
Clovis Oncology, Inc. recently announced that the FDA has granted approval to label expansion of its PARP inhibitor, Rubraca (rucaparib). The drug is now approved as a maintenance treatment in recurrent ovarian cancer patients who have received one prior platinum-based chemotherapy. The drug can now also be prescribed irrespective of BRCA-mutation in the second-line setting.
The FDA approval was based on data from the confirmatory phase III study — ARIEL 3 which showed that Rubraca led to significant improvement in progression-free survival in such patients.
Please note that Rubraca had received accelerated approval for the treatment of advanced BRCA-mutant ovarian cancer in third or later line setting in December 2016. With the latest approval, the accelerated approval was converted to regular one for this indication. The drug is under review in Europe for this indication with a decision expected in this quarter.
Shares of Clovis were up 5.9% on Mar 6, after the news surfaced. However, the stock has lost 18.4% so far this year, underperforming the industry’s decline of 11.8%.
With the latest approval, Rubraca comes at par with other approved PARP inhibitors for treatment of ovarian cancer — AstraZeneca’s (AZN - Free Report) Lynparza and TESARO’s Zejula. All the drugs are now approved in patients irrespective of the BRCA-mutation status, creating a level playing field for all the players.
Pfizer (PFE - Free Report) is also evaluating its PARP inhibitor, talazoparib, in a phase I study in several advanced or recurrent solid tumors.
Moreover, earlier this February, the National Comprehensive Cancer Network (“NCCN”) added Rubraca as maintenance therapy for third or later line ovarian cancer patients to its clinical practice guidelines in oncology ovarian cancer.
The year 2018 has started well for Clovis with a positive recommendation for Rubraca’s approval in Europe in third or later line ovarian cancer patients, addition to the NCCN guidelines and the latest label expansion in the United States. Moreover, after a potential approval in Europe, Clovis will seek further approval of the drug as maintenance therapy in the expanded patient population.
These positive developments are expected to boost the company’s top line. However, it remains to be seen how the three PARP inhibitors perform in an equally competing field.
Meanwhile, a phase III confirmatory study, ARIEL4, is evaluating Rubraca compared with chemotherapy on patients, who have failed two prior lines of therapy. Clovis is also looking to expand Rubraca’s label into additional indications, like prostrate, breast and pancreatic cancers, among others either as monotherapy or in combination with other agents.
Clovis Oncology, Inc. Price
Clovis Oncology, Inc. Price | Clovis Oncology, Inc. Quote
Zacks Rank
Clovis currently carries a Zacks Rank #4 (Sell). You can seethe complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks Editor-in-Chief Goes "All In" on This Stock
Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.
Download it free >>